Antibacterial evaluation of a collection of norfloxacin and ciprofloxacin derivatives against multiresistant bacteria

International Journal of Antimicrobial Agents

Volumn 28, Issue 1, 2006, Pages 19-24

  Vila, J ^a   Sanchez Cespedes J ^a   Sierra, J M ^a   Piqueras, M ^b   Nicolas E ^b   Freixas, J ^c   Giralt, E ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Cenavisa SA   (Spain)

Author keywords

Acinetobacter baumannii; Ciprofloxacin derivatives; Multiresistant bacteria; Norfloxacin derivatives; Stenotrophomonas maltophilia

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; CIPROFLOXACIN DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; NORFLOXACIN; NORFLOXACIN DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UB 8902; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DILUTION; DRUG SCREENING; DRUG SENSITIZATION; DRUG SYNTHESIS; ESCHERICHIA COLI; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; MICROBIAL SENSITIVITY TESTS; NORFLOXACIN;

EID: 33745185999     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.02.013     Document Type: Article

References (24)

1. Arroyo L.A., Garcia-Curiel A., Pachon-Ibañez M.E., et al. Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii. J Clin Microbiol 43 (2005) 903-905
2. Ribera A., Ruiz J., Jimenez de Anta M.T., and Vila J. Effect of an efflux pump inhibitor on the MIC of nalidixic acid for Acinetobacter baumannii and Stenotrophomonas maltophilia clinical isolates. J Antimicrob Chemother 49 (2002) 697-698
3. Rodriguez-Hernandez M.J., Jimenez-Mejias M.E., Pichardo C., Cuberos L., Garcia-Curiel A., and Pachon J. Colistin efficacy in an experimental model of Acinetobacter baumannii endocarditis. Clin Microbiol Infect 10 (2004) 581-584
4. Vila J. Mechanisms of antimicrobial resistance in Acinetobacter baumannii. Rev Med Microbiol 9 (1998) 87-97
5. Yoon J., Urban C., Terzian C., Mariano N., and Rahal J.J. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 48 (2004) 753-757
6. Caylan R., Kaklikkaya N., Aydin K., et al. An epidemiological analysis of Stenotrophomonas maltophilia strains in a university hospital. Jpn J Infect Dis 57 (2004) 37-40
7. Fadda G, Spanu T, Ardito F, et al.; Italian Epidemiological Observatory. Antimicrobial resistance among non-fermentative Gram-negative bacilli isolated from the respiratory tracts of Italian inpatients: a 3-year surveillance study by the Italian Epidemiological Survey. Int J Antimicrob Agents 2004;23:254-61.
8. Bearden D.T., and Danziger L.H. Mechanism of action of and resistance to quinolones. Pharmacotherapy 21 (2001) 224S-232S
9. Hooper D.C. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 7 (2001) 337-341
10. Vila J. Fluoroquinolone resistance. In: Whitte D.G., Alekshun M.N., and McDermott P.F. (Eds). Frontiers in antimicrobial resistance: a tribute to Stuart B. Levy (2005), ASM Press, Washington, DC 41-52
11. Martínez-Martínez L., Pascual A., and Jacoby G.A. Quinolone resistance from a transferable plasmid. Lancet 351 (1998) 797-799
12. Vila J., Sánchez-Céspedes J., and Giralt E. Old and new strategies for the discovery of antibacterial agents. Curr Med Chemist Anti-Infect Agents 4 (2005) 337-353
13. Vila J., Ruiz J., Navia M., Becerril B., et al. Spread of amikacin resistance in Acinetobacter baumannii strains isolated in Spain due to an epidemic strain. J Clin Microbiol 37 (1999) 758-761
14. Escribano E., Calpena A.C., Garrigues T.M., Freixas J., Doménech J., and Moreno J. Structure-absorption relationships of a series of 6-fluoroquinolones. Antimicrob Agents Chemother 41 (1997) 1996-2000
15. Merino V., Freixas J., Bermejo M.V., Garrigues T.M., Moreno J., and Pla-Delfina J.M. Biophysical models as an approach to study passive absorption in drug development: 6-fluoroquinolones. J Pharm Sci 84 (1995) 777-782
16. National Committee for Clinical Laboratory Standards. Performance standard for antimicrobial susceptibility testing. Fifteenth Informational Supplement. M100-S15 (2005), NCCLS, Wayne, PA
17. Vila J., Ruiz J., Goñi P., Marcos A., and Jimenez de Anta M.T. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 39 (1995) 1201-1203
18. Vila J., Ruiz J., Goñi P., and Jimenez de Anta M.T. Quinolone resistance in the topoisomerase IV parC gene of Acinetobacter baumannii. J Antimicrob Agents 39 (1997) 757-762
19. Ribera A., Domenech-Sánchez A., Ruiz J., Benedí J., Jimenez de Anta M.T., and Vila J. Mutations in gyrA and parC QRDRs are not relevant for quinolone resistance in epidemiological unrelated Stenotrophomonas maltophilia clinical isolates. Microb Drug Resist 8 (2002) 245-252
20. Valdezate S., Vindel A., Echeita A., et al. Topoisomerase II and IV quinolone-resistance determining regions in Stenotrophomonas maltophilia in clinical isolates with different levels of quinolone susceptibility. Antimicrob Agents Chemother 46 (2002) 665-671
21. Valdezate S., Vindel A., Saéz-Nieto J.A., Baquero F., and Cantón R. Preservation of topoisomerase genetic sequences during in vivo and in vitro development of high-level resistance to ciprofloxacin in isogenic Stenotrophomonas maltophilia strains. J Antimicrob Chemother 56 (2005) 220-223
22. Shen L.L., Mitscher L.A., Sharma P.N., et al. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug-DNA binding model. Biochemistry 28 (1989) 3886-3894
23. Palumbo M., Gatto B., Zagotto G., and Palu G. On the mechanism of action of quinolone drugs. Trends Microbiol 1 (1993) 232-234
24. Vila J., Ruiz J., Marco F., et al. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob Agents Chemother 38 (1994) 2477-2479